Marlissa is a monophasic birth control. It contains ethinyl estradiol and levonorgestrel for pregnancy prevention.
Indications for use
Marlissa is prescribed predominantly for oral contraception. But it also can be applied in the treatment of functional disorders of the menstrual cycle inclusively of dysmenorrhea of non-organic cause, dysfunctional metrorrhagia and premenstrual syndrome.
Mechanism of action
Marlissa belongs to birth control combined drug containing estrogen and progestin. When it is taken orally, this preparation inhibits the pituitary gonadotropic hormones’ secretion.
The progestin component contains a derivative of 19-nortestosterone, levonorgestrel which is superior in activity to the hormone of the yellow body and performs on the level of receptors without preliminary metabolic transformations.
Ethinyl estradiol as an estrogen component provides the blockade of the releasing factors (LH and FSH) of the hypothalamus, inhibiting the secretion of the pituitary gland by gonadotropic hormones. It leads to suppression of maturation and ovulation ready for fertilization. The contraceptive effect is associated with ethinyl estradiol.
It maintains a high level of viscosity of the cervical mucus. Along with the contraceptive effect in the case of a regular application of this birth control drug normalizes the menstrual cycle and helps prevent the development of a number of gynecological diseases, including of a tumor genesis.
Mode of application and dosage
Marlissa is applied once a day within a 28-days course. The course is conducted without any breaks. When the first package is left the next one package should be started. The drug is washed down with a glass of water.
- Hepatic insufficiency;
- Congenital hyperbilirubinemia;
- Liver tumors (hemangioma, liver cancer);
- Malignant tumors (primarily breast or endometrium cancer);
- Presence or indication in the medical history of severe cardiovascular and cerebrovascular diseases;
- Thromboembolism and predisposition to it;
- Diabetes mellitus of severe course (accompanied by retinopathy and microangiopathy);
- Sickle cell anemia;
- Chronic hemolytic anemia;
- Vaginal bleeding of unclear etiology;
- Otosclerosis with hearing impairment;
- Congenital hyperlipidemia;
- Marfan syndrome;
- Age over 40.
Marlissa may cause the following side effects:
- breast tenderness;
- weight gain;
- decreased libido;
- mood swings;
- intermenstrual bloody secretion;
- eyelid edema;
- visual dysfunctions;
- discomfort when wearing contact lenses (these phenomena are a temporary character and disappear after cancellation without prescribing any therapy).
With a long-lasting application, there observed the following negative reactions:
- hearing loss;
- generalized pruritus;
- calf muscle cramps;
- increased frequency of epileptic seizures.
Rarely there are the following adverse reactions:
- decreased glucose tolerance;
- increased blood pressure;
- thrombosis and venous thromboembolism;
- skin rashes;
- a change in the nature of vaginal secretion;
- vaginal candidiasis;
- increased fatigue;
Hormone effect is enhanced predominantly by barbiturates, some anti-epileptic drugs (carbamazepine, phenytoin), sulfonamides, pyrazolone derivatives.
Antimicrobial drugs (ampicillin, rifampicin, chloramphenicol, neomycin, polymyxin B, sulfonamides, tetracyclines) influence the reduction in contraceptive effect which is associated with changes in intestinal microflora.
What if I miss a dose?
In case of skipping the administration of Marlissa birth control, it is necessary to take the drug within the next 12 hours. At a reception interval of more than 36 hours, a reliable contraceptive effect is not guaranteed.
However, despite this, you should continue taking the drug from the package started (except for unused pills) in order to prevent the premature onset of menstruation associated with the drug withdrawal. During this period it is recommended to use other non-hormonal contraceptive methods such as condoms or spermicides.
Marlissa and pregnancy
Marlissa is contraindicated during pregnancy and lactation.